English | 简体中文 | 繁體中文 | 한국어 | 日本語
 Press Releases for Monday, March 6, 2023
Linkedin Influencer Rachel Mitchell Joins Plato's Board 
23:30 HKT/SGT
Palladium One and MetalCorp Enter into Definitive Agreement for a Business Combination 
19:30 HKT/SGT
Palladium One and MetalCorp Enter into Definitive Agreement for a Business Combination 
19:30 HKT/SGT
World Premiere of the All-New Crown Series 
18:46 HKT/SGT
世界听力日 「乜嘢话」长者听力慈惠计划启动礼 
16:59 HKT/SGT
Axiata Joins Global Telcos to Deploy GSMA Open Gateway at MWC Barcelona 2023 
16:00 HKT/SGT
日立パワーソリューションズが太陽光発電協調型風力発電システムを初納入 
16:00 HKT/SGT
Sri Trang Agro-Industry Founder Somwang Sincharoenkul Passes on at 97 
16:00 HKT/SGT
Two Indonesian Elementary Schools Built with Support of Mitsubishi Motors Hold Opening Ceremonies 
15:55 HKT/SGT
医思健康香港自建旗舰宠物医院正式开幕 
15:52 HKT/SGT
醫思健康香港自建旗艦寵物醫院正式開幕 
15:51 HKT/SGT
EC Healthcare Opened the First Organic Flagship Veterinary Hospital in Hong Kong 
15:50 HKT/SGT
KDDI・三菱重工・NECネッツエスアイ、データセンター内のサーバーを液体冷却、冷却電力の94%減を達成 
15:45 HKT/SGT
MC Signs Integrated Railway Systems and Trackwork Contract for North-South Commuter Railway Extension Project in the Philippines 
14:16 HKT/SGT
Society Pass Inc. (Nasdaq: SOPA)'s NusaTrip Continues Expansion in Southeast Asia (SEA), Extending Services to Vietnam 
14:00 HKT/SGT
三菱商事、フィリピン共和国 南北通勤鉄道延伸向け鉄道システム一式契約締結について発表 
11:00 HKT/SGT
Honda、米国で燃料電池(FC)定置電源の実証運用を開始 
10:54 HKT/SGT
エーザイ、「LEQEMBI」についてアルツハイマー病治療薬としてフル承認に向けた生物製剤承認一部変更申請(sBLA)が米国FDAに受理され、優先審査に指定 
10:00 HKT/SGT
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease 
09:58 HKT/SGT
Honda's Zero Emission Stationary Fuel Cell Provides Back Up Power to a Data Center 
09:43 HKT/SGT
 ACN Search:
 
Paw Pro GmbH Announces $1.5M Partnership with Health Reasoning to Launch Innovative Web3 Platform
 
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575